Keros Therapeutics (KROS) Operating Income (2019 - 2025)
Historic Operating Income for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$15.4 million.
- Keros Therapeutics' Operating Income rose 7377.3% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 12136.16%. This contributed to the annual value of -$210.8 million for FY2024, which is 2406.25% down from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Operating Income is -$15.4 million, which was up 7377.3% from -$39.8 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Operating Income peaked at $152.0 million during Q1 2025, and registered a low of -$58.7 million during Q3 2024.
- Moreover, its 5-year median value for Operating Income was -$32.0 million (2022), whereas its average is -$24.0 million.
- As far as peak fluctuations go, Keros Therapeutics' Operating Income crashed by 55680.23% in 2022, and later surged by 41359.45% in 2025.
- Quarter analysis of 5 years shows Keros Therapeutics' Operating Income stood at -$4.9 million in 2021, then plummeted by 556.8% to -$32.0 million in 2022, then crashed by 45.35% to -$46.5 million in 2023, then dropped by 14.64% to -$53.3 million in 2024, then surged by 71.11% to -$15.4 million in 2025.
- Its Operating Income was -$15.4 million in Q3 2025, compared to -$39.8 million in Q2 2025 and $152.0 million in Q1 2025.